Use of recombinant factor VIII Advate in paediatric patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F09%3A00100632" target="_blank" >RIV/00843989:_____/09:00100632 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Use of recombinant factor VIII Advate in paediatric patients

Original language description

Recombinant products represent unambiguous technological progress, and are very likely to increase the safety of haemophilia treatment. It is evidenced by their growing consumption, particularly in paediatric patients, in all developed countries which have recommended recombinant products as the treatment of choice. The higher incidence of the inhibitor reported in some publications has not been fully confirmed till this time, and, in addition, the 3rd generation recombinant products appear to be less immunogenic compared to products of previous generations. The lower volume of the product after dissolution is also advantageous for paediatric use.Our limited experience in the treatment with rFVIII Advate is very good, and we are going to struggle to include the recombinant products among fully reimbursed routine treatment of haemophilia.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FG - Paediatrics

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hämostaseologie

ISSN

0720-9355

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

Suppl.1

Country of publishing house

DE - GERMANY

Number of pages

3

Pages from-to

—

UT code for WoS article

000272214600014

EID of the result in the Scopus database

—